摘要 |
The invention provides neratinib for use in a method for treating early stage HER-2 positive breast cancer, wherein the method comprises delivering neratinib therapy to early stage HER-2 positive breast cancer patients at the completion of at least twelve months of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy. |